The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1190
August 30, 2004
View Complete Issue         Table of Contents 2019 
Tinidazole (Tindamax) - A New Anti-Protozoal Drug
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tinidazole (Tindamax) - A New Anti-Protozoal Drug
August 30, 2004 (Issue: 1190)
Tinidazole (Tindamax - Presutti Labs), an oral antiprotozoal drug similar to metronidazole (Flagyl, and others), has been approved by the FDA for treatment of trichomoniasis in adults and for treatment of giardiasis, intestinal amebiasis and amebic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tinidazole (Tindamax) - A New Anti-Protozoal Drug
Article code: 1190b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.